Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
AbstractThis review provides an overview of 50 years of basic and clinical research on an oncolytic avian virus, Newcastle Disease Virus (NDV), which has particular anti-neoplastic and immune stimulatory properties. Of special interest is the fact that this biological agent induces immunogenic cell death and systemic anti-tumor immunity. Furthermore, localized oncolytic virotherapy with NDV was shown to overcome systemic tumor resistance to immune checkpoint blockade immunotherapy. Clinical experience attests to low side effects and a high safety profile. This is due among others to the strong virus-induced type I interferon response. Other viral characteristics are lack of interaction with host cell DNA, lack of genetic recombination and independence of virus replication from cell proliferation. In this millennium, new recombinant strains of viruses are being produced with improved therapeutic properties. Clinical applications include single case observations, case series studies and Phase I to III studies. View Full-Text
Share & Cite This Article
Schirrmacher, V. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines 2016, 4, 16.
Schirrmacher V. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines. 2016; 4(3):16.Chicago/Turabian Style
Schirrmacher, Volker. 2016. "Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!" Biomedicines 4, no. 3: 16.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.